We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio There was no significant difference in ...

It is essential that health care providers identify predictors of excess mortality in patients with T2D to optimally target risk-reduction strategies. Patients with T2D would benefit from more ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis ...

Investigators found that in patients with diabetes and cancer, sodium glucose cotransporter-2 inhibitors were associated with a higher risk of diabetic ketoacidosis and fracture and a lower risk of ...

Although good glucose control in type 2 diabetes significantly improves patient outcomes, having many options for oral therapy can complicate treatment decisions. In this context, a drug’s risk of ...

As the tide of obesity and its complications are on the rise, there is an urgent need for new drugs with weight-lowering and beneficial metabolic properties. Obesity-related disorders, such as ...

We thank Dr. Mithoowani and colleagues for their excellent review on the investigation and management of erythrocytosis,1 which provides a comprehensive overview and approach to a common presentation ...

In work that could someday improve treatments for epilepsy, scientists have the first three-dimensional structure of a member of a large family of human proteins that carry charged particles -- ions - ...